SCHEMBL4575645

SCHEMBL4575645

CC(=O)NC(Cc1csc2ccccc12)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.59
CTSL P07711 1/20 0.53
CTSS P25774 1/20 0.53
CTSK P43235 1/20 0.53
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
PKM P14618 1/20 0.48
CYP2A6 P11509 2/20 0.47
F10 P00742 2/20 0.46
TAAR1 Q96RJ0 1/20 0.46
ALOX15 P16050 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TP53 P04637 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
POLB P06746 1/20 0.44
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
OPRK1 P41145 2/20 0.43
TNF P01375 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805209 0.86 MMP2 (0.52) TACR1CTSLCTSSCTSKMMP2
SCHEMBL16203423 0.86 MMP2 (0.52) TACR1CTSLCTSSCTSKMMP2
SCHEMBL6020582 0.84 CTSS (0.74) TACR1CTSLCTSSCTSKMMP2
SCHEMBL22872329 0.84 MMP2 (0.50) TACR1CTSLCTSSCTSKMMP2
SCHEMBL8668238 0.84 TACR1 (0.43) TACR1CTSLCTSSCTSKALOX15
SCHEMBL16750041 0.84 MMP2 (0.50) TACR1CTSLCTSSCTSKMMP2
SCHEMBL20214369 0.83 CYP2A6 (0.50) TACR1CTSLCTSSCTSKMMP2
SCHEMBL3599165 0.83 CTSS (0.76) TACR1CTSLCTSSCTSKMMP2
SCHEMBL999047 0.83 CTSS (0.76) TACR1CTSLCTSSCTSKMMP2
SCHEMBL29908025 0.83 CTSS (0.76) TACR1CTSLCTSSCTSKMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194524-A1 Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof JERINI AG (DE) 2008-08-14 US disclosed
EP-1703912-A1 COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF Jerini AG (DE) 2006-09-27 EP disclosed
WO-2005063259-A1 COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2005-07-14 WO disclosed
US-5472978-A Tachykinin antagonists for treating pain, migraine and antiinflammatory agents MERCK SHARP & DOHME LTD. (GB) 1995-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194524-A1 Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof CCNB1, CCNB2, CCNA1 TACR1 1953/4885CTSL 2760/4885CTSS 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.